October 29–31, 2018
Meet Genedata experts at European Antibody Congress in Basel, Switzerland.
Don't miss the opportunity to see how Genedata solutions efficiently support the whole biopharmaceutical R&D workflow, including screening and protein engineering, expression and purification, characterization and analysis of protein therapeutics, cell line design and development, bioprocess optimization, and quality control of biologicals.
To get more information about Genedata solutions, please contact email@example.com.
Industrializing IO Therapeutic Discovery Platforms: Multispecifics, Engineered TCRs and CARs
Novel classes of bio-molecules are currently evaluated for their use in cancer immunotherapy. Bi- and multi-specific antibodies, Ab-cytokine fusion proteins, non-Ig scaffolds, chimeric antigen receptors (CARs), engineered TCRs and TCR-based bispecific constructs promise significant advantages. However, these highly engineered molecules pose new challenges in design, engineering, cloning, expression, purification, and analytics. Genedata Biologics offers an infrastructure that addresses these challenges and enables the industrialization of these various novel therapeutic platforms.